2026-01-14 - Analysis Report
**Report for Johnson & Johnson (JNJ)**

**Company Overview**
Johnson & Johnson is a multinational healthcare company that develops and markets medical devices, pharmaceuticals, and consumer products.

**Return Rate Comparison**
The return rate of Johnson & Johnson (56.96%) is lower than that of S&P 500 (93.94%). The degree of divergence on the last day of the data is -36.98% (93.94% - 56.96%).

**Performance Analysis**

| Year | CAGR | MDD | Alpha | Beta | Capital (B) |
|------|------|-----|-------|-------|-------------|
| 2016-2018 | 6.0% | 16.8% | 3.0% | 0.7 | 310.9B |
| 2017-2019 | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020 | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021 | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022 | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023 | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024 | -30.0% | 13.8% | -50.0% | 0.2 | 348.4B |
| 2023-2025 | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

**Stock Price Fluctuations**
Recent stock price fluctuations:

* Close: $213.65
* Last-market: {'price': 213.65, 'previousClose': 209.72, 'change': 1.87}
* 5-day SMA: $208.20
* 20-day SMA: $207.79
* 60-day SMA: $200.65

**RSI, PPO, Delta_Previous_Relative_Divergence, and Expected_Return**
Market Risk Indicator (MRI): 0.70
RSI: 63.51
PPO: 0.02
Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium
Recent (20 days) relative divergence change: -6.80 (-): worsening
7-day Rank change: -3 (-): rank down
7-day Dynamic Expected Return change: -22.70 (-): worsening
Expected Return: -74.90%

**Recent News and Significant Events**

* 2026-01-13: Here’s What Lifted Johnson & Johnson (JNJ) in Q4 - Yahoo Finance (link)
* 2026-01-13: Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week - TechStock² (link)
* 2025-12-30: More Upside For JNJ Stock In 2026? - Forbes (link)
* 2026-01-13: Narwhal Capital Management Has $17.87 Million Stock Holdings in Johnson & Johnson $JNJ - MarketBeat (link)
* 2026-01-09: J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort - AJMC (link)
* 2026-01-13: What's Powering J&J's MedTech Growth Ahead of Q4 Release? - The Globe and Mail (link)

**Analyst Opinions**
* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
	+ Opinions: 24
	+ Target Price (avg/high/low): 212.00 / 240.00 / 155.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|------|-----|---------|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

**Revenue and Profitability Analysis**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

**Capital and Profitability Analysis**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

**Comprehensive Analysis**
Johnson & Johnson (JNJ) has had a relatively low return rate compared to S&P 500, and its stock price has been fluctuating in recent times. The company's performance analysis shows varying results across different time periods, with some periods experiencing high CAGRs and others experiencing losses. The RSI and PPO indicators suggest that the stock may be overbought, while the Delta_Previous_Relative_Divergence and Expected_Return analysis indicate a high risk of loss. The recent news and significant events highlight the company's ongoing growth in the medtech sector. Analyst opinions are generally positive, but the expected return is negative. Overall, the comprehensive analysis suggests that investors should exercise caution when considering an investment in Johnson & Johnson.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.